IMU 0.00% 5.2¢ imugene limited

"Imugene’s PFS HR was comparable to the landmark Genentech/Roche...

  1. 262 Posts.
    lightbulb Created with Sketch. 162
    "Imugene’s PFS HR was comparable to the landmark Genentech/Roche registrational ToGA study
    (PFS HR of 0.71), which also examined the effect of Herceptin plus chemotherapy versus SOC
    chemotherapy alone in advanced HER-2 positive gastric cancer."

    So the benefit is the same as Herceptin, but my understanding is that the safety / side effects of Herceptin can be nasty. Can anyone elaborate?
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Last
5.2¢
Change
0.000(0.00%)
Mkt cap ! $382.1M
Open High Low Value Volume
5.3¢ 5.3¢ 5.2¢ $160.0K 3.048M

Buyers (Bids)

No. Vol. Price($)
23 882045 5.2¢
 

Sellers (Offers)

Price($) Vol. No.
5.3¢ 457736 5
View Market Depth
Last trade - 16.10pm 19/08/2024 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.